0001209191-18-022971.txt : 20180403
0001209191-18-022971.hdr.sgml : 20180403
20180403163027
ACCESSION NUMBER: 0001209191-18-022971
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180403
FILED AS OF DATE: 20180403
DATE AS OF CHANGE: 20180403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ratcliffe Liam
CENTRAL INDEX KEY: 0001547100
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38443
FILM NUMBER: 18733829
MAIL ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE - SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Unum Therapeutics Inc.
CENTRAL INDEX KEY: 0001622229
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 465308248
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 CAMBRIDGE PARK DRIVE
STREET 2: SUITE 3100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-945-5576
MAIL ADDRESS:
STREET 1: 200 CAMBRIDGE PARK DRIVE
STREET 2: SUITE 3100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: Unum Therapeutics, Inc.
DATE OF NAME CHANGE: 20141014
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-04-03
0
0001622229
Unum Therapeutics Inc.
UMRX
0001547100
Ratcliffe Liam
C/O UNUM THERAPEUTICS INC.
200 CAMBRIDGE PARK DRIVE, SUITE 3100
CAMBRIDGE
MA
02140
1
0
0
0
Common Stock
2018-04-03
4
C
0
622772
A
622772
I
See Footnote
Common Stock
2018-04-03
4
C
0
622773
A
622773
I
See Footnote
Common Stock
2018-04-03
4
P
0
275000
12.00
A
897772
I
See Footnote
Common Stock
2018-04-03
4
P
0
275000
12.00
A
897773
I
See Footnote
Series B Preferred Stock
2018-04-03
4
C
0
977835
D
Common Stock
622772
0
I
See Footnote
Series B Preferred Stock
2018-04-03
4
C
0
977836
D
Common Stock
622773
0
I
See Footnote
Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares have no expiration date.
The shares are held directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLBA I. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Each of the Reporting Person, Ronald M. Hunt and Vijay K. Lathi (each a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Continued in Footnote 3
Continued from Footnote 2: Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 of any other purpose, except to the extent of their respective pecuniary interests therein.
The shares are held directly by New Leaf Ventures III, L.P. ("NLV III").New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. NLV Management III is the sole general partner of NLV Associates III. NLVP is the investment adviser of NLV III.Each of NLV Associates and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Each of the Members may be deemed to have shared voting and dispositive power of these securities. Continued in Footnote 5
Continued from Footnote 4: Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 of any other purpose, except to the extent of their respective pecuniary interests therein.
/s/ Amoli Pandya, Attorney-in-Fact
2018-04-03